GNFT.PA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (8 May 2024 @ 19:21):

Stats
今日成交量	51 183.00
平均成交量	109 288
市值	166.95M
EPS	€0 ( 2024-04-03 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-5.79
ATR14	€0.00900 (0.27%)

音量相关性

長: 0.08 (neutral)

短: 0.42 (neutral)

Signal:(60.89) Neutral

Genfit SA 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Genfit SA 相关性 - 货币/商品

0.70
( moderate )

0.71
( moderate )

0.00
( neutral )

0.73
( moderate )

0.00
( neutral )

0.79
( moderate )

Genfit SA 财务报表

Annual	2023
营收:	€28.57M
毛利润:	€28.22M (98.81 %)
EPS:	€-0.580

FY	2023
营收:	€28.57M
毛利润:	€28.22M (98.81 %)
EPS:	€-0.580

FY	2022
营收:	€20.20M
毛利润:	€19.95M (98.77 %)
EPS:	€-0.480

FY	2021
营收:	€80.07M
毛利润:	€0.00 (0.00 %)
EPS:	€0.641

Financial Reports:

No articles found.

Genfit SA

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.